This study will evaluate the effects of an investigational drug in combination with
chemotherapy in patients with stage IIIB/IV non-small cell lung cancer. This study will
measure the effects of this combination on progression of lung cancer, cancer response to
treatments, and development of cancer-related bone lesions.